for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Enzo Biochem, Inc.

ENZ.N

Latest Trade

3.23USD

Change

-0.01(-0.31%)

Volume

33,408

Today's Range

3.21

 - 

3.27

52 Week Range

2.33

 - 

4.46

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
3.24
Open
3.22
Volume
33,408
3M AVG Volume
3.04
Today's High
3.27
Today's Low
3.21
52 Week High
4.46
52 Week Low
2.33
Shares Out (MIL)
47.56
Market Cap (MIL)
153.61
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Enzo Biochem Reports Fourth Quarter Results

Harbert Discovery Fund Nominates Two Independent Candidates To Enzo Biochem Board

James Roumell Dissolves Share Stake In Enzo Biochem Inc

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Enzo Biochem, Inc.

Enzo Biochem, Inc. is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company's segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. It offers a menu of molecular and other clinical laboratory tests or procedures. Enzo Life Sciences manufactures, develops and markets products and tools to clinical research, drug development and bioscience research customers. Enzo Therapeutics is a biopharmaceutical venture that develops multiple approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases. Its products in the development pipeline include a range of assays for detection of various women's health infectious agents, as well as for use in the identification of pathogens for other markets.

Industry

Healthcare Facilities

Contact Info

60 EXECUTIVE BLVD

+1.516.7555500

http://www.enzo.com/

Executive Leadership

Barry W. Weiner

President, Chief Financial Officer, Principal Accounting Officer, Treasurer, Director

Elazar Rabbani

Chairman of the Board, Chief Executive Officer, Secretary

James M. O'Brien

Executive Vice President - Finance

Bruce A. Dey

Vice President - Sales and Marketing, Enzo Clinical Labs

Dieter Schapfel

Chief Medical Director,

Key Stats

Price To Earnings (TTM)
64.36
Price To Sales (TTM)
1.89
Price To Book (MRQ)
1.79
Price To Cash Flow (TTM)
27.80
Total Debt To Equity (MRQ)
5.81
LT Debt To Equity (MRQ)
5.35
Return on Investment (TTM)
2.89
Return on Equity (TTM)
2.39

Latest News

Latest News

BRIEF-Enzo Biochem Says CO Considering All Available Options For Challenging Federal Circuit Panel's Decision

* ENZO BIOCHEM - U.S. COURT OF APPEALS ISSUED OPINION AFFIRMING LOWER COURT JUDGMENTS OF PATENT INVALIDITY FOR U.S. PATENT NOS. 6,992,180 & 8,097,405

BRIEF-Enzo Biochem Enters Settlement Agreement With Roche

* ENZO BIOCHEM INC - CO ALONG WITH ITS UNIT ENTERED INTO A SETTLEMENT AGREEMENT AS OF FEBRUARY 5, 2019 WITH ROCHE - SEC FILING

BRIEF-Enzo Biochem Says Patent Trial And Appeal Board Has Denied A Petition Filed By Hologic For Inter Partes Review

* ENZO BIOCHEM INC - PATENT TRIAL AND APPEAL BOARD HAS DENIED A PETITION FILED BY HOLOGIC FOR INTER PARTES REVIEW Source text for Eikon: Further company coverage:

BRIEF-Enzo Biochem Reports Q2 Adjusted Loss Per Share $0.04

* QTRLY LOSS PER SHARE $0.02 Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Austock Group ‍Says Enzo Silverii Retires As Chief Financial Officer​

* GORDON JOSEPH WILL BE ACTING CFO Source text for Eikon: Further company coverage:

BRIEF-Enzo Biochem Q1 Non-GAAP Loss Per Share $0.01

* Q1 REVENUE $27.7 MILLION VERSUS $26.3 MILLION Source text for Eikon: Further company coverage:

BRIEF-‍Enzo Biochem announces NYS department of health's approval of a new women's health infectious disease panel​

* Enzo Biochem announces NYS department of health's approval of a new women's health infectious disease panel Source text for Eikon: Further company coverage:

CORRECTED-BRIEF-Enzo Biochem Q4 non-gaap net income of $0.00 per share (Sept 27)

(Corrects headline and third bullet to Q4 non-gaap net income of $0.00/share from non-gaap loss of $0.04/share) Enzo Biochem Inc:

BRIEF-Enzo Biochem files for mixed shelf of up to $150 million

* Files for mixed shelf of up to $150 million - SEC filing Source text for Eikon: Further company coverage:

BRIEF-Enzo Biochem says federal judge in a U.S. Court has entered an order in action entitled Enzo Life Sciences v. Abbott Laboratories ​

* Enzo Biochem says a federal judge in a U.S. Court has entered an order in action entitled Enzo Life Sciences, Inc. v. Abbott Laboratories - sec filing

BRIEF-Enzo Biochem announces NY state health department approval of New Women’S Health Diagnostics

* Enzo Biochem announces New York State Health Department approval of new Women’s Health Diagnostics

BRIEF-Enzo Biochem Q2 non-gaap loss per share $0.02

* Enzo Biochem reports increased second quarter operating results

BRIEF-S2G Biochem to collaborate with Mondelez for new sweetener process

* S2g Biochem announces collaboration with Mondelez International for new sweetener process

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up